What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Enzyme
- Gene
Raphael Mechoulam focuses on Cannabinoid, Cannabinoid receptor, Pharmacology, Endocannabinoid system and Cannabinoid receptor type 2.
His Cannabinoid study incorporates themes from Agonist, Cannabinoid receptor antagonist and Ligand.
His Cannabinoid receptor study is associated with Internal medicine.
His Pharmacology research is multidisciplinary, incorporating elements of Tetrahydrocannabinol, Cannabidiol, Dexanabinol and Traumatic brain injury.
His Endocannabinoid system study combines topics from a wide range of disciplines, such as Signal transduction, Neuroscience, Immunology and 2-Arachidonoylglycerol.
He combines subjects such as Cannabinoid Receptor Modulators, Progenitor cell, Endogenous agonist, Cannabinoid Receptor Agonists and Cannabinoid receptor type 1 with his study of Cannabinoid receptor type 2.
His most cited work include:
- ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR (4525 citations)
- Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. (2333 citations)
- International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors (2187 citations)
What are the main themes of his work throughout his whole career to date?
Raphael Mechoulam spends much of his time researching Pharmacology, Cannabinoid, Cannabinoid receptor, Cannabidiol and Endocannabinoid system.
The Pharmacology study which covers Tetrahydrocannabinol that intersects with Organic chemistry.
His biological study spans a wide range of topics, including Agonist, Endocrinology and Stereochemistry.
His studies in Anandamide, Cannabinoid receptor type 2 and Depolarization-induced suppression of inhibition are all subfields of Cannabinoid receptor research.
His research links GPR18 with Cannabinoid receptor type 2.
His research on Endocannabinoid system frequently links to adjacent areas such as Neuroscience.
He most often published in these fields:
- Pharmacology (35.91%)
- Cannabinoid (31.75%)
- Cannabinoid receptor (24.60%)
What were the highlights of his more recent work (between 2011-2021)?
- Cannabidiol (18.65%)
- Pharmacology (35.91%)
- Cannabinoid (31.75%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Cannabidiol, Pharmacology, Cannabinoid, Endocannabinoid system and Cannabinoid receptor.
The study incorporates disciplines such as Inflammation, Immunology and Anxiety in addition to Cannabidiol.
His Pharmacology research includes themes of Receptor, Antagonist, Anxiolytic, Receptor antagonist and In vivo.
His Cannabinoid research focuses on subjects like Endocrinology, which are linked to Methylazoxymethanol acetate.
The concepts of his Endocannabinoid system study are interwoven with issues in Neuroscience, Neuroprotection, Tetrahydrocannabinol, Endogeny and Traumatic brain injury.
His study in Cannabinoid receptor type 2, Anandamide and Cannabinoid Receptor Agonists is carried out as part of his Cannabinoid receptor studies.
Between 2011 and 2021, his most popular works were:
- The Endocannabinoid System and the Brain (549 citations)
- Endocannabinoid signaling at the periphery: 50 years after THC (348 citations)
- Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (178 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
